Cardiogramme
Logo   Accueil | Table des matières | Téléchargements | Liens |   Mentions légales   | Contact |Abréviations
Logo  

Bibliographie

Lectures conseillées

BABER U, MASTORIS I, MEHRAN R. Balancing ischaemia and bleeding risks with novel oral anticoagulants. Nat Rev Cardiol 2014 ; 11 :693-703
BARON TH, KAMATH PS, McBANE RD. Management of antithrombotic therapy in patients undergoing invasive procedures. N Engl J Med 2013; 368:2113-24
DOUKETIS JD, SPYROPOULOS AC, SPENCER FA, et al. Perioperative management of antithrombotic therapy : Antithrombotic therapy and prevention of thrombosis, 9th ed. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, Chest 2012 ; 141 (2 suppl) : e326S-50S
FARAONI D, LEVY JH, ALBALADEJO P, et al. Updates in the perioperative and emergency management of non-vitamin K antagonist oral anticoagulants. Critic Care 2015; 19:203
FARAONI D, SAVAN V, LEVY JH, THEUSINGER MH. Goal-directed coagulation managment in the perioperative period of cardiac surgery. J Cardiothorac Vasc Anesth 2013 ; 27 : 1347-54
GARCIA DA, BAGLIN TP, WEITZ JI, et al. Parenteral anticoagulants: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (Suppl 2):e24S-e43S
KOZEK-LANGENECKER SA. Perioperative coagulation monitoring. Best Pract Res Clin Anaesthesiol 2010 ; 24 : 27-40
KOZEK-LANGENECKER SA, AFSHARI A, ALBALADEJO P, et al. Management of severe perioperative bleeding : Guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol 2013 ; 30 : 270-82
MARCUCCI CE, SCHOETKKER P, ed. Perioperative hemostasis. Coagulation for anesthesiologists. Heidelberg: Springer, 2015, 454 pp
ROZENTAL T, SHORE-LESSERSON L. Pharmacologic management of coagulopathy in cardiac surgery: An update. J Cardiothorac Vasc Anesth 2012; 26:660-79
TANAKA KA, BOLLIGER D, VADIAMUDI R, NIMMO A. Rotational thromboelastometry (ROTEM)-based coagulation management in cardiac surgery and major trauma. J Cardiothorac Vasc Anesth 2012 ; 26 :1083-93
TANAKA KA, KOR DJ. Emerging haemostatic agents and patient blood management. Best Pract Res Clin Anaesthesiol 2013 ; 27 : 141-60
WEBER CF, KLAGES M, ZACHAROWSKI K. Perioperative coagulation management during cardiac surgery. Curr Opin Anaesthesiol 2013 ; 26 : 60-84

Références

1 ADAMS RLC, BIRD RJ. Review article: Coagulation cascade and therapeutic update: Relevance to nephrology. Part I: Overview of coagulation, thrombophilia and history of anticoagulants. Nephrol 2009; 14:462-70
2 AGENO WA, GALLUS AS, WITTKOWSKY A, et al. Oral anticoagulant therapy: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (Suppl 2):e44S-e88S
3 AIRD WC. Hemostasis and irreducible complexity. J Thrombosis Haemost 2003 ; 1 :227-30
4 Angiolillo DJ, FIRSTENBERG MS, PRICE MJ, et al. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery. JAMA 2012; 307:265-74
5 ANGIOLILLO DJ, UENO M, GOTO S. Basic principles of platelet biology and clinical implications. Circ J 2010; 74:597-607
6 ANTONIOU T, KAPETANAKIS EI, THEODORAKI K, et al. Cardiac surgery in patients with heparin-induced thrombocytopenia using preoperatively determined dosages of Iloprost. Heart Surg Forum 2002; 5:354-7
7 ARTANG R, ROME E, NIELSEN JD, et al. Meta-analysis of randomized controlled trials on risk of myocardial infarction from the use of oral direct thrombin inhibitor. Am J Cardiol 2013 ; doi :10.1016/amjcard2013.08.027
8 ASIMAKOPOULOS G. The inflammatory response to CPB: the role of leucocyte filtration. Perfusion 2002; 17:7-10
8a ASMIS LM. Coagulation factor concentrates. In: MARCUCCI CE, SCHOETKKER P, ed. Perioperative hemostasis. Coagulation for anesthesiologists. Heidelberg: Springer, 2015, 177-204
9 AUGOUSTIDES JGT. The inflammatory response to cardiac surgery with cardiopulmonary bypass : shoud steroid prophylaxis be routine ? J Cardiothorac Vasc Anesth 2012 ; 26 :952-8
10 AVIDAN MS, LEVY JH, SCHOLZ J, et al. A phase III, double-blind, placebo-controlled, multicenter study on the efficacy of recombinant human antithrombin in heparin-resistant patients scheduled to undergo cardiac surgery necessitating cardiopulmonary bypass. Anesthesiology 2005 ; 102 : 276-84
11 BAGOLY Z, KONCZ Z, MUSZBEK L. Factor XIII, clot structure, thrombosis. Thromb Res 2012; 129:382-7
12 BARASH PG, et al, eds. Précis d’anesthésie clinique. Paris: Arnette (Wolters Kluwer France), 2008, 1205-14
13 BARBAR S, NOVENTA F, ROSSETTO V, et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism : the Padua Prediction Score. J Thromb Haemost 2010 ; 8 :2450-7
14 BARON TH, KAMATH PS, McBANE RD. Management of antithrombotic therapy in patients undergoing invasive procedures. N Engl J Med 2013; 368:2113-24
15 BARRETT YC, WANG Z, et al. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost 2010; 104:1263-71
16 BAUER KA. Recent progress in anticoagulant therapy: oral direct inhibitors of thrombin and factor Xa. J Thromb Haemost 2011; 9(suppl 1):12-19
17 BAUERSACHS R, BERKOWITZ SD, BRENNER B, et al, EINSTEIN investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363:2499-510
18 BEATTIE WS, KARKOUTI K. Con: Aprotinin has a good efficacy and safety profile relative to other alternatives for prevention of bleeding in cardiac surgery. Anesth Analg 2006; 103:1360-4
19 BECATTINI C, AGNELLI G, SCHENONE A, et al. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med 2012; 366:1959-67
20 BEIERLEIN W, SCHEULE AM, DIETRICH W, et al. Forty years of clinical aprotinin use: A review of hypersensitivity reactions. Ann Thorac Surg 2005; 79:7412-8
20a BEYER-WESTENDORF J, GELBRICHT V, FORSTER K, et al. Peri-interventional management of novel oral anticoagulants in daily care : results from prospective Dresden NOAC registry. Eur Heart J 2014 ; 35:1888-96
21 BIANCARI F, AIRAKSINEN KEJ, LIP GYH. Benefits and risks of using clopidogrel before coronary artery bypass surgery: Systemic review and meta-analysis od randomized trials and observational studies. J Thorac Cardiovasc Surg 2012; 143:665-75
22 BIANCARI F, RIMPILAINEN R. Meta-analysis of randomised trials comparing the effectiveness of miniaturised versus conventional cardiopulmonary bypass in adult cardiac surgery. Heart 2009; 95:964-9
23 BIRNIE DH, HEALEY JS, WELLS GA, et al. Pacemaker or defibrillator surgery without interruption of anticoagulation. N Engl J Med 2013 ; 368 :2084-93
24 BODY SC, MAZER CD. Pro: Aprotinin has a good efficacy and safety profile relative to other alternatives for prevention of bleeding in cardiac surgery. Anesth Analg 2006; 103:1354-9
25 BOLLIGER D, GÖRLINGER K, TANAKA KA. Pathophysiology and treatment of coagulopathy in massive hemorrhage and hemodilution. Anesthesiology 2010; 113:1205-19
25a BONHOMME F, HAFEZI F, BOEHLEN F, HABRE W. Management of antithrombotic therapies in patients scheduled for eye surgery. Eur J Anaesthesiol 2013; 30:449-54
26 BOODHWANI M, WILLIAMS K, BABAEV A, et al. Ultrafiltration reduces blood transfusion following cardiac surgery: a meta-analysis. Eur J Cardiothorac Surg 2006; 30:892-7
26a BOUNAMEAUX H, CAMM AJ. Edoxaban : An update on the new oral direct factor Xa inhibitor. Drugs 2014 ; 74 :1209-31
27 BROWN C, JOSHI B, FARADAY N, et al. Emergency cardiac surgery in patients with acute coronary syndromes : a review of the evidence and perioperative inmplications of medical and mechanical therapeutics. Anesth Analg 2011 ; 112 : 277-99
28 BROWN JR, BIRKMEYER NJO, O’CONNOR GT. Meta-analysis comparing the effectiveness and adverse outcomes of antifibrinolytic agents in cardiac surgery. Circulation 2007; 125:2801-13
29 CAMM AJ, BOUNAMEAUX H. Edoxaban. A new oral direct factor Xa inhibitor. Drugs 2011; 71:1503-26
30 CAPPABIANCA G, ROTUNNO C, DE LUCA TUPPUTI L, et al. Protective effects of steroids in cardiac surgery: A meta-analysis of randomized double-blind trials. J Cardiothorac Vasc Anesth 2011; 25:156-65
31 CASATI V, GUZZON D,OPPIZZI M, et al. Tranexamic acid compared with high-dose aprotinin in primary elective heart operations: effects on perioperative bleeding and allogenic transfusions. J Thorac Cardiovasc Surg 2000; 120:520-7
32 CASBARD AC, WILLIAMSON LM, MURPHY MF, et al. The role of prophylactic fresh frozen plasma in decreasing blood loss and correcting coagulopathy in cardiac surgery. A systematic review. Anaesthesia 2004 ; 59 : 550-8
32a CASONATO A, SPONGA S, PONTARA E, et al. Von Willebrand factor abnormalities in aortic valve stenosis : pathophysiology and impact on bleeding. Thromb Haemost 2011 ; 106 :58-66
33 CHANDLER WL, VELAN T. Estimating the rate of thrombin and fibrin generation in vivo during cardiopulmonary bypass. Blood 2003; 101:4355-62
34 CHANDLER WL, VELAN T. Plasmin generation and D-dimer formation during cardiopulmonary bypass. Blood Coag Fibrinolysis 2004; 15:583-91
35 CHASSOT PG, ANGELILLO-SCHERRER A, MARCUCCI C. Perioperative antiplatelet and antithrombotic therapy. In : MARCUCCI C, SCHOETKER P, editors. Perioperative haemostasis and coagulation for anaesthesiologists. Berlin : Springer Verlag, 2013, in press
36 CHOWDARY P, SAAYMAN AG, PAULUS U, et al. Efficacy of standard dose and 30 ml/kg fresh frozen plasma in correcting laboratory parameters of haemostasis in critically ill patients. Br J Haematol 2004 ; 125 : 69-73
37 COLEMAN CI, RIGALI VT, HAMMOND J, et al. Evaluating the safety implications of aprotinin use: The Retrospective Evaluation of Aprotinin in Cardio Thoracic Surgery (REACTS). J Thorac Cardiovasc Surg 2007; 133:1547-52
38 CONNOLLY SJ, EIKELBOOM J, JOYNER C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364:806-17
39 COPPENS M, EIKELBOOM JW, GUSTAFSSON D, WEITZ JI. Translational success stories. Development of direct thrombin inhibitors. Circ Res 2012; 111:920-9
40 CRUDEN NL, MORCH K, WONG DR, et al. Clopidogrel loading dose and bleeding outcomes in patients undergoing urgent cronary artery bypass grafting. Am Heart J 2011; 161:404-10
40a CUKER A, HUSSEINZADEH H. Laboratory measurement of the anticoagulant activity of edoxaban : a systematic review. J Thromb Thrombolysis 2015 ; 39 :288-94
41 Czerny M, Baumer H, Kilo J, et al. Inflammatory response and myocardial injury following coronary artery bypass grafting with or without cardiopulmonary bypass. Eur J Cardiothorac Surg 2000; 17: 737-42
42 DAVI G, PATRONO C. Platelet activation and atherothrombosis. N Engl J Med 2007; 357:2482-94
43 DAVIE EW, RATNOFF OD. Waterfall sequence for intrinsic blood clotting. Science 1964; 164:1310-2
44 DE FOE GR, ROSS CS, OLMSTEAD EM, et al. Lowest hematocrit on bypass and adverse outcomes associated with coronary artery bypass grafting. Ann Thorac Surg 2001; 71:769-76
45 DESPOTIS GJ, JOIST JH, HOGUE CW, et al. More effective suppression of hemostatic system activation in patients undergoing cardiac surgery by heparin dosing based on heparin blood concentrations rather than ACT. Thromb Haemost 1996 ; 76 : 902-8
46 Diegeler A, Doll N, Rauch T, et al. Humoral immune response during coronary artery bypass grafting: A comparison of limited approach, "off-pump" technique, and conventional cardiopulmonary bypass. Circulation 2000; 102: III95-100
47 DIELMAN JM, NIERICH AP, ROSSEEL PM, et al. Intraoperative high-dose dexamethasone in cardiac surgery :a randomized controlled trial. JAMA 2012 ; 308 :1761-7
48 DIETRICH W, BUSLEY R, SPANNAGL M, et al. The influence of antithrombin substitution on heparin sensitivity and activation of hemostasis during coronary artery bypass graft surgery : a dose-finding study. Anesth Analg 2013 ; 116 :1223-30
49 DOUKETIS JD. Perioperative management of patients who are receiving warfarin therapy: an evidence-based and practical approach. Blood 2011; 117:5044-9
50 DOUKETIS JD, BERGER PB, DUNN AS, et al. The perioperative management of antithrombotic therapy. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008; 133:299S-339S
50a DOUKETIS JD, HEALEY JS, BRUECKMANN M, et al. Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery ot procedure. Thromb Haemost 2015 ; 113:625-32
51 DOUKETIS JD, SPYROPOULOS AC, SPENCER FA, et al. Perioperative management of antithrombotic therapy : Antithrombotic therapy and prevention of thrombosis, 9th ed. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, Chest 2012 ; 141 (2 suppl) : e326S-50S
52 DUNNING J, VERSTEEGH M, FABBRI A, et al. Guidelines on antiplatelet and anticoagulation management in cardiac surgery. Eur J Cardiothorac Surg 2008; 34:73-92
53 ELAHI MM, YII M, MATATA BM. Significance of oxidants and inflammatory mediators in blood of patients undergoing cardiac surgery. J Cardiothorac Vasc Anesth 2008; 22:455-67
54 EMA-European Medicines Agency. European Medicines Agency recommends lifting suspension of aprotinin 2011.
http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Antifibrinolytic_medicines/WC500122924.pdf
55 ENGOREN MC, HABIB RH, ZACHARIAS A, et al. Effect of blood transfusion on long-term survival after cardiac operation. Ann Thorac Surg 2002; 74:1180-6
56 FALK E, SHAH PK, FUSTER V. Coronary plaque disruption. Circulation 1995; 92:657-71
56a FARAONI D, LEVY JH, ALBALADEJO P, et al. Updates in the perioperative and emergency management of non-vitamin K antagonist oral anticoagulants. Critic Care 2015; 19:203
57 Favaloro EJ, LIPPI G, FRANCHINI M. Contemporary platelet function testing. Clin Chem Lab Med 2010; 48:579-98
58 FENGER-ERIKSEN C, JENSEN TM, KRISTENSEN BS, et al. Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy : a randomised, placebo-controlled clinical trial. J Thromb Haemost 2009 ; 7 : 795-802
59 FERGUSSON DA, HEBERT PC, MAZER CD, et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 2008; 358:2319-31
60 FERRARIS VA, BROWN JR, DESPOTIS GJ, et al. 2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. Ann Thorac Surg 2011; 91:944-82
61 FERREIRO JL, SIBBING D, ANGIOLILLO DJ. Platelet function testing and risk of bleeding complications. Thromb Haemost 2010; 103:1128-35
62 FINLEY A, GREENBERG C. Heparin sensitivity and resistance : management during cardiopulmonary bypass. Anesth Analg 2013 ; 116 :1210-22
63 FONTES ML, MATHEW JP, RINDER HM, et al. Atrial fibrillation after cardiopulmonary bypass is associated with monocyte activation. Anesth Analg 2005; 101:17-23
64 FRANZ A, BRAUNLICH P, et al. The effects of hydroxyethyl starches of varying molecular weights on platelet function. Anesth Analg 2001 ; 92 : 1402-7
65 FRÄSSDORF J, DE HERT S, SCHLACK W. Anaesthesia and myocardial ischaemia/reperfusion injury. Br J Anaesth 2009; 103:89-98
66 GALANIS T, THOMSON L, PALLADINO M, et al. New oral anticoagulants. J Thromb Thrombolysis 2011; 31:310-20
67 GARCIA DA, BAGLIN TP, WEITZ JI, et al. Parenteral anticoagulants: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (Suppl 2):e24S-e43S
68 GAVILLET M, ANGELILLO-SCHERRER A. Quantification of the anticoagulatory effect of novel anticoagulants and management of emergencies. Cardiovasc Med 2012; 15:170-9
69 GIUGLIANO RP, RUFF CT, BRAUNWALD E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013 ; 369 :2093-104
70 GODIER A, MICHOT A, LE BONNIEC B, et al. Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model. Anesthesiology 2012; 116:94-102
71 GOGARTEN W, VANDERMEULEN E, VAN AKEN H, et al. Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology. Eur J Anaesthesiol 2010; 27:999-1015
72 GOMBOTZ H, KNOTZER H. Preoperative identification of patients with increased risk for perioperative bleeding. Curr Opin Anesthesiol 2013 ; 26 :82-90
73 GOODNOUGH LT, SHANDER A. Patient blood management. Anesthesiology 2012 ; 116 : 1367-76
74 GOODNOUGH LT, SHANDER A. Current status of pharmacologic therapies in patient blood management. Anesth Analg 2013 ; 116 : 15-34
74a GÖRLINGER K, DIRKMANN D, HANKE AA ; et al. First-line therapy with coagulation factor concentrates combined with point-of-care coagulation testing is associated with decrease allogeneic blood transfusion in cardiovascular surgery. Anesthesiology 2011 ; 115 : 1179-91
74b GÖRLINGER K, FRIES D, DIRKMANN D, et al. Reduction of fresh frozen plasma requirements by perioperative point-of-care coagulation management with early calculated goal-directed therapy. Transfus Med Hemother 2012 ; 39 :104-13
75 GORMLEY SMC, McBRIDE WT, ARMSTRONG MA, et al. Plasma and urinary cytokine homeostasis and renal function during cardiac surgery without cardiopulmonary bypass. Cytokine 2002; 17:61-5
75a GOROG DA, FUSTER V. Platelet function tests in clinical cardiology. Unfulfilled expectations. J Am Coll Cardiol 2013; 61:2115-29
76 GRONCHI F, RANUCCI M. Perioperative coagulation in cardiovascular surgery. In : MARCUCCI C, SCHOETKER P, editors. Perioperative hemostasis. Coagulation for anesthesiologists. Heidelberg : Springer Verlag, 2014, 243-66
77 GROVER FL. The Society of thoracic Surgeons national Database. Current status and future directions. Ann Thorac Surg 1999; 68:367-73
78 GUNAYDIN S, FARSAK B, KOKAKULAK M, et al. Clinical performance and biocompatibility of poly(2-methoxyethylacrylate)-coated extracorporeal circuits. Ann Thorac Surg 2002; 74:819-24
79 GUYATT GH, AKL EA, CROWTHER M, et al. American College of Chest Physicians antithrombotic therapy and prevention of thrombosis panel. Executive summary : antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 : 7S-47S
80 HAASE M, HAASE-FIELITZ A, BELLOMO R, et al. Sodium bicarbonate to prevent increases in serum creatinine after cardiac surgery: a pilot double-blind, randomized controlled trial. Crit Care Med 2009; 37:39-47
81 HABIB RH, ZACHARIAS A, SCHWANN TA, et al. Adverse effects of low hematocrit during cardiopulmonary bypass in the adult: should current practice be changed ? J Thorac Cardiovasc Surg 2003; 125:1438-50
81a HABIB RH, ZACHARIAS A, SCHWANN TA, et al. Role of hemodilutional anemia and transfusion during cardiopulmonary bypass in renal injury after coronary revascularization: Implications on operative outcome. Crit Care Med 2005; 33:1749-56
82 HALL R. Identification of inflammatory mediators and their modulation by strategies for the management of the Systemic Inflammatory Response during cardiac surgery. J Cardiothorac Vasc Anesth 2013 ; 27 : 983-1033
83 HALL TS. The pathophysiology of cardiopulmonary bypass: The risks and benefits of hemodilution. Chest 1995: 100:88-94
84 HAMM CW, BASSAND JP, AGEWALL S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2011; 32:2999-3054
85 HANKEY GJ, EIKELBOOM JW. Dabigatran etexilate: a new oral thrombin inhibitor. Circulation 2011; 123: 1436-50
86 HANSSON EC, HAKIMI CS, ARSTRÖM-OLSSON K, et al. Effects of ex vivo platelet supplementation on platelet aggregability in blood samples from patients treated with acetylsalicylic acid, clopidogrel, or ticagrelor. Br J Anaesth 2013 ; doi :10.1093/bja/aet339
86a HARROP-GRIFFITHS W, COOK T, GILL H, et al. Regional anaesthesia and patients with abnormalities of coagulation. The Association of Anaesthesists of Great Britain & Ireland, The Obstetric Anaesthesits’Association, Regional Anaesthesia UK. Anaesthesia 2013 ; 68 :966-72
87 HEALEY JS, EIKELBOOM J, DOUKETIS J, et al. Periprocedural bleeding and thromboemblic events with dabigatran compared with warfarin. Circulation 2012; 126: 343-8
88 HEALTH CANADA. Health Canada decision on Trasylol (aprotinin) 2011. http://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/_2011/2011_124-eng.php.
88a HEIDBUCHEL H, VERHAMME P, ALINGS M, et al. European Heart Rythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013 ; 15:625-51
89 HELD C, ASENBLAD N, BASSAND JP, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery. J Am Coll Cardiol 2011; 57:672-84
90 HENNEIN HA. Inflammation after cardiopulmonary bypass: therapy for the postpump syndrome. Semin Cardiothorac Vasc Anesth 2001; 5:236-55
91 HENRY DA, CARLESS PA, MOXEY AJ, et al. Antifibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2011 ; CD 001886
92a HICKEY M, GATIEN M, TALJAARD M, et al. Outcomes of urgent warfarin reversal with frozen plasma versus prothrombin complex concentrate in the emergency department. Circulation 2013; 128:360-4
92 HIIPPALA ST, MYLLYLA GJ, VAHTERA EM. Hemostatic factors and replacement of major blood loss with plasma-poor red cell concentrates. Anesth Analg 1995 ; 81 : 360-5
93 HILLIS LD, SMITH PK, ANDERSON JL, et al. 2011 ACCF/AHA Guideline for coronary artery bypass graft surgery. J Am Coll Cardiol 2011; 58:e123-e210
94 HOFFMAN M. Remodeling the blood coagulation cascade. J Thromb Thrombolysis 2003; 16:17-20
95 HOFFMAN M. A cell-based model of coagulation and the role of factor VIIa. Blood Reviews 2003; 17 (Suppl 1):S1-S5
96 HOFFMAN M, MONROE DM. A cell-based model of hemostasis. Thromb Haemost 2001; 85:958-65
97 HOGUE CW, LONDON MJ. Aprotinin use during cardiac surgery: A new or continuing controversy ? Anesth Analg 2006; 103:1067-70
98 HOLBROOK A, SCHULMAN S, WITT DM, et al. Evidence-based management of anticoagulant therapy. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (Suppl 2):e152S-e184S
98a HORLOCKER TT, WEDEL DJ, ROWLINGSON JC, et al. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine evidence-based guidelines (third edition). Reg Anesth Pain Med 2010; 35:64-101
99 HULTEN E, JACKSON JL, DOUGLAS K, et al. The effect of early, intensive statin therapy on acute coronary syndrome: a meta-analysis of randomized controlled trials. Arch Intern Med 2006; 166:1814-21
100 INNERHOFER P, KIENAST J. Principles of perioperative coagulopathy. Best Pract Res Clin Anaesthesiol 2010; 24:1-14
100a JACKSON SL, PETERSON GM, VIAL JH, et al. Outcomes in the management of atrial fibrillation : clinical trials results can apply in practice. Intern Med J 2001 ; 31 :329-36
101 JACOB M, SMEDIRA N, BLACKSTONE E, et al. Effect of timing of chronic preoperative aspirin discontinuation on morbidity and mortality in coronary artery bypass surgery. Circulation 2011; 123:577-83
102 JOBES DR. Safety issues in heparin and protamin administration for extracorporeal circulation. J Cardiothorac Vasc Anesth 1998; 12:17-20
103 JONAS RA, WYPIJ D, ROTH SJ, et al. The influence of hemodilution on outcome after hypothermic cardiopulmonary bypass: results of a randomized trial in infants. J Thorac Cardiovasc Surg 2003; 126:1765-74
103a KAATZ S, KOUIDES PK, GARCIA DA ; et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol 2012 ; 87:S141-S145
104 KARKOUTI K, BEATTIE WC, DATTILO KM, et al. A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery. Transfusion 2006; 46:327-38
105 KARKOUTI K, BEATTIE WC, WIJEYSUNDERA DN, et al. Recombinant factor VIIa for intractable blood loss after cardiac surgery : A propensity score-matched case-control analysis. Transfusion 2005; 45:26-34
106 KARKOUTI K, CALLUM J, CROWTHER MA, et al. The relationship between fibrinogen levels after cardiopulmonary bypass and large volume red cell transfusion in cardiac surgery : an observational study. Anesth Analg 2013 ; 117 : 14-22
106a KARKOUTI K, McCLUSKEY SA, CALLUM J, et al. Evaluation of a novel transfusion algorithm employing point-of-care coagulation assays in cardiac surgery. Anesthesiology 2015; 122:560-70
107 KARLSSON M, TERNSTRÖM I, HYLLNER M, et al. Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery. A prospective randomised pilot study. Thromb Haemost 2009 ; 102 : 137-44
108 KATZ J, FELDMAN MA, BASS EB, et al. Risks and benefits of anticoagulant and antiplatelet medication use before cataract surgery. Ophthalmology 2003; 110:1784-8
109 KELTON JG, ARNOLD DM, BATES SM. Nonheparin anticoagulants for heparin-induced thrombocytopenia. N Engl J Med 2013; 368:737-44
110 KHORANA AA ; FRANCIS CW, BLUMBERG N, et al. Blood transfusions, thrombosis and mortality in hospitalized patients with cancer. Arch Intern Med 2008 ; 168 : 2377-81
111 KILGER E, WEISS F, BRIEGEL J, et al. Stress doses of hydrocortisone reduce severe systemic inflammatory response syndrome and improve early outcome in a risk group of patients after cardiac surgery. Crit Care Med 2003; 31:1068-74
112 KIM JHJ, NEWBY LK, CLARE RM, et al. Clopidogrel use and bleeding after coronary artery bypass graft surgery. Am Heart J 2008; 156:886-92
113 KIMMEL SE, SEKERES M, BERLIN JA, et al. Mortality and adverse events after protamine administration in patients undergoing cardiopulmonary bypass. Anesth Analg 2002; 94:1402-8
114 KINCAID EH, ASHBURN DA, HOYLE JR, et al. Does the combination of aprotinin and angiotensin-converting enzyme inhibitor cause renal failure after cardiac surgery ? Ann Thorac Surg 2005; 80:1388-93
115 KOCH CG, LI L, DUNCAN AI, et al. Transfusion in coronary artery bypass grafting is associated with reduced long-term survival. Ann Thorac Surg 2006; 81:1650-7
116 KOR DJ, STUBBS JR, GAJIC O. Perioperative coagulation management – fresh frozen plasma. Best Pract Res Clin Anaesthesiol 2010; 24: 51-64
117 KORTE WC, SZADKOWSKI C, GÄHLER A, et al. Factor XIII substitution in surgical cancer patients at high risk for intraoperative bleeding. Anesthesiology 2009; 110: 239-45
118 KOSTER A, BÖRGERMANN J, ZITTERMANN A, et al. Moderate dosage of tranexamic acid during cardiac surgery with cardiopulmonary bypass and convulsive seizures : incidence and clinical outcome. Br J Anaesth 2013 ; 110 : 34-40
119 KOSTER A, BUZ S, et al. Bivalirudin anticoagulation during cardiac surgery : a single-center experience in 141 patients. Perfusion 2009 ; 24 : 7-11
120 KOSTER A, DYKE CM, ALDEA G, et al. Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: Results of the CHOOSE-ON trial. Ann Thorac Surg 2007; 83:572-7
121 KOSTER A, KUKUCKA M, BACH F, et al. Anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II and renal impairment using heparin and the platelet glycoprotein Iib/IIIa antagonist tirofiban. Anesthesiology 2001; 94:245-51
122 KOSTER A, SCHIRMER U. Re-evaluation of the role of antifibrinolytic therapy with lysine analogs during cardiac surgery in the post aprotinin era. Curr Opin Anaesthesiol 2011; 24:92-7
123 KOZEK-LANGENECKER SA. Perioperative coagulation monitoring. Best Pract Res Clin Anaesthesiol 2010 ; 24 : 27-40
123a KOZEK-LANGENECKER SA, AFSHARI A, ALBALADEJO P, et al. Management of severe perioperative bleeding : Guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol 2013 ; 30 : 270-82
124 KRAJEWSKI S, KURZ J, NEUMANN B, et al. Short-acting P2Y12 blockade to reduce platelet dysfunction and coagulopathy during experimental extracoroporeal circulation and hypothermia. Br J Anaesth 2012; 108:912-21
124a KRISTENSEN SD, KNUUTI J, SARASTE A, et al. 2014 ESC/ESA Guidelines on non-cardiac surgery : cardiovascular assessment and management. Eur Heart J 2014 ; 35:2383-431
125 KWAK YL. KIM JC, CHOI YS, et al. Clopidogrel responsiveness regardless of the discontinuation date predicts increased blood loss and transfusion requirement after off-pump coronary artery bypass graft surgery. J Am Coll Cardiol 2010; 56:1994-2002
126 Laffey JG, Boylan JF, Cheng DC. The systemic inflammatory response to cardiac surgery: implications for the anesthesiologist. Anesthesiology 2002; 97: 215-52
127 LASSEN MR, GALLUS A, RASKOB GE, et al, ADVANCE-3 investigators. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 2010; 363:2487-98
128 LAVIGNE D, Vasopressin and methylene blue: alternate therapies in vasodilatory shock. Semin Cardiothorac Vasc Anesth 2010; 14:186-9
129 LEE GC, KICZA AM, LIU KY, et al. Does rotational thromboelastometry (ROTEM) improve prediction of bleeding after cardiac surgery ? Anesth Analg 2012 ; 115 : 499-506
130 LE GAL G, RIGHINI M, ROY PM, et al. Prediction of pulmonary embolism in the emergency department: The revised Geneva score. Ann Intern Med 2006; 144:165-71
131 LEVI M, LEVY JH, ANDERSEN HF, et al. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med 2010 ; 363 : 1791-800
132 LEVY JH, MONTES F, SZLAM F, et al. The in vitro effect of antithrombin III on the activated coagulation time in patients on heparin therapy. Anesth Analg 2000 ; 90 : 1076-9
133 LEVY JH, SZLAM F, TANAKA K, SNIECIENSKI RM. Fibrinogen and hemostasis: A primary hemostatic target for the management of acquired bleeding. Anesth Analg 2012; 114:261-74
134 LIAM BL, PLOCHL W, COOK DJ, et al. Hemodilution and whole body balance during normothermic cardiopulmonary bypass. J Cardiothorac vasc Surg 1998; 115:1203-8
135 LINKINS LA, DANS AL, MOORES LK, et al. Treatment and prevention of heparin-induced thrombocytopenia. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (Suppl 2):e495S-e530S
136 LOWENSTEIN E, ZAPOL WM. Protamine reactions, explosive mediator release and pulmonary vasoconstriction. Anesthesiology 1990; 73:373-8
136a LU G, DEGUZMMAN FR, HOLLENBACH SJ, et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 2013; 19:446-53
137 MAHARAJ C, LAFFEY JG. New strategies to control the inflammatory response in cardiac surgery. Curr Opin Anesthesiol 2004; 17:35-48
137a MAHLA E, Suarez TA, Bliden KP, et al. Platelet function measurement-based strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary artery bypass graft surgery. Circ Cardiovasc Interv 2012; 5:261-9
138 MAJEED A, SCHULMAN S. Bleeding and antidotes in new oral anticoagulants. Best Pract Res Clin Haematology 2013 ; 26 :191-202
139 MANGANO DT, MIAO Y, VUYLSTEKE A, et al. Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery. JAMA 2007; 297:471-9
140 MANGANO DT, TUDOR I, DIETZEL C, et al. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006; 354:353-65
141 MANGOUSH O, PURKAYASTHA S, HAJ-YAHIA S, et al. Heparin-bonded circuits versus nonheparin-bonded circuits: an evaluation of their effect on clinical outcomes. Eur J Cardiothorac Surg 2007; 31:1058-69
142 MANSON L, WEITZ JI, PODOR TJ, et al. The variable anticoagulant response to unfractioned heparin in vivo reflects binding to plasma proteins rather than clearance. J Lab Clin Med 1997; 130:649-655
143 MARTIN K, WIESNER G, BREUER T, et al. The risks of aprotinin and tranexamic acid in cardiac surgery: A one-year follow-up of 1188 consecutive patients. Anesth Analg 2008; 107:1783-90
143a MARTINEZ M, GRAF L, TSAKIRIS DA. Congenital bleeding disorders. In: MARCUCCI CE, SCHOETKKER P, ed. Perioperative hemostasis. Coagulation for anesthesiologists. Heidelberg: Springer, 2015, 71-87
144 McILLROY DR, MYLES OS, PHILLIPS LE, SMITH JA. Antifibrinolytics in cardiac surgical patients receiving aspirin: a systematic review and meta-analysis. Br J Anaesth 2009; 102:168-78
145 McMULLAN V, ALSTON RP. Aprotinin and cardiac surgery : a sorry tale of evidence misused. Br J Anaesth 2013 ; 110 : 675-8
146 MEGA JL, BRAUNWALD E, WIWIOTT SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366:9-19
147 MEHRAN R, RAO SV, BHATT DL, et al. Standardized bleeding definitions for cardiovascular clinical trials. A consensus report from the Bleeding Academic Research Consortium. Circulation 2011 ; 123 :2736-47
148 Menasche P. The systemic factor: the comparative roles of cardiopulmonary bypass and off-pump surgery in the genesis of patient injury during and following cardiac surgery. Ann Thorac Surg 2001; 72: S2260-5; discussion S5-6
149 MONGERO LB, BECK JR (eds). On bypass. Advanced perfusion techniques. Policy and procedure guidelines (CP36): Cold agglutinins. Totowa (NJ, USA): Humana Press 2010, 426-8
150 MOSESSON MW. Update on antithrombin I (fibrin). Thromb Haemost 2007; 98:105-8
151 MUECK W, LENSING AWA, AGNELLI G, et al. Rivaroxaban. Population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet 2011; 50:675-86
151a MUECK W, SCHWERS S, STAMPFUSS J. Rivaroxaban and other novel oral anticoagulants : pharmacokinetics in healthy subject, specific patient populations and relevance of coagulation monitoring. Thrombosis Journal 2013 ; 11 : 10
151b MUECK W, STAMPFUSS J, KUBITZA D, BECKA M. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet 2014 ; 53:1-16
152 MUKADAM ME, PRITCHARD D, RIDDINGTON D, et al. Case 7-2001. Management during cardiopulmonary bypass of patients with presumed fish allergy. J Cardiothorac Vasc Anesth 2001; 15:512-9
153 MURAD MH, STUBBS JR, GANDHI MJ, et al. The effect of plasma transfusion on morbidity and mortality : a systematic review and meta-analysis. Transfusion 2010 ; 50 : 1370-83
154 MURPHY GJ, REEVES BC, ROGERS CA, et al. Increased mortality, postoperative morbidity, and cost after red blood cell transfusion in patients having cardiac surgery. Circulation 2007; 116:2544-52
155 MURPHY GS, WHITLOCK RP, GUTSCHE JT, et al. Steroids for adult cardiac surgery with cardiopulmonary bypass : update on dose and key randomized trials. J Cardiothorac Vasc Anesth 2013 ; 27 :1053-9
155a NALLA BP, FREEDMAN J, HARE GMT, MAZER CD. Update on blood conservation for cardiac surgery. J Cardiothorac Vasc Anesth 2012; 26:117-33
156 Nathoe HM, Van Dijk D, Jansen EWL, et al. A comparison of on-pump and off-pump coronary bypass surgery in low-risk patients. N Engl J Med 2003; 348:394-402
157 NIELSEN VG, ASMIS LA. Hypercoagulability in the perioperative period. Best Pract Res Clin Anaesthesiol 2010; 24:133-44
158 NIELSEN VG, STEENWYK BL, HOLMAN WL, et al. Mechanical circulatory device thrombosis: a new paradigm linking hypercoagulation and hypofibrinolysis. Am Soc Artif Int Org J 2008; 54:351-8
159 NIJJER S, WATSON G, ATHANASIOU T, et al. Safety of clopidogrel being continued until the time of coronary artery bypass grafting in patients with acute coronary syndrome: a meta-analysis of 34 studies. Eur Heart J 2011; 32:2970-88
160 NUTALL GA, BROST BC, CONNIS RT, et al. Practice guidelines for perioperative blood transfusion and adjuvant therapies. Anesthesiology 2006; 105:198-208
161 NUTESCU EA, SPINLER SA, WITTKOWSKY A, et al. Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. Ann Pharmacother 2009; 43:1064-83
162 OHRI SK, BOWLES CW, MATHIE RT, et al. Effect of cardiopulmonary bypass perfusion protocols on gut tissue oxygenation and blood flow. Ann Thorac Surg 1997; 64:163-8
163 OPAL SM. The host response to endotoxin, antipolysaccharide strategies, and the management of severe sepsis. Int J Med Microbiol 2007; 297:365-77
164 ORTMANN E, BESSER MW, KLEIN AA. Antifibrinolytic agents in current anaesthetic practice. Br J Anaesth 2013 ; 111 :549-63
165 PAGEL PS. Myocardial protection by volatile anesthetics in patients undergoing cardiac surgery : a critical review of the laboratory and clinical evidence. J Cardiothorac Vasc Anesth 2013 ; 27 :972-82
166 PATEL MR, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365:883-81
167 PATTI G, CANNON CP, MURPHY SA, et al. Clinical benefit of statin pretreatment in patients undergoing percutaneous coronary intervention: a collaborative patient-level meta-analysis of 13 randomized studies. Circulation 2011; 123:1622-32
168 PERNOD G, ALBALADEJO P, GODIER A, et al. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor Xa inhibitors : proposals of the Working Group on Perioperative Haemostasis (GIHP) – March 2013. Arch Cardiovasc Dis 2013 ; 106 :382-93
168a PERZBORN E, HEITMEIER S, LAUX V, BUCHMULLER A. Reversal of rivaroxaban-induced anticoaguéation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro. Thrombos Res 2014 ; 133 :671-81
169 PEYROU V, LORMEAU JC, HERAULT JP, et al. Contribution of erythrocytes to thrombin generation in whole blood. Thromb Haemost 1999 ; 81 : 400-6
170 PORTOLA. Portola reports statistically significant results from phase 3 ANNEXA-A randomized, placebo-controlled study. Portola has secured two commercial manufacturing contracts in order to supply the global market. Communiqués de presse de Portola, 16 Octobre 2014 (Portola Pharmaceuticals Inc, South San Francisco, CA 94080, USA)
171 Puskas JD, Williams WH, Duke PG, et al. Off-pump coronary artery bypass grafting provides complete revascularization with reduced myocardial injury, transfusion requirements, and length of stay: A prospective randomized comparison of two-hundred unselected patients undergoing off-pump versus conventional coronary artery bypass surgery. J Thorac Cardiovasc Surg 2003; 125:797-808
172 RAHE-MEYER N, SOLOMON C, HANKE A, et al. Effects of fibrinogen concentrate as first-line therapy during major aortic replacement surgery. Anesthesiology 2013 ; 118 : 40-50
173 RANUCCI M, BALDUINI A, DITTA A ; et al. A systematic review of biocompatible cardiopulmonary bypass circuits and clinical outcome. Ann Thorac Surg 2009 ; 87 : 1311-9
174 RANUCCI M, BARYSHNIKIVA E, SORO G, et al. Multiple electrode whole-blood aggregometry and bleeding in cardiac surgery patients receiving thienopyridines. Ann Thorac Surg 2011; 91:123-30
175 RANUCCI M, CAZZANIGA A, SORO G, et al. The anti-thrombin III saving effect of reduced systemic heparinization and heparin-coated circuits. J Cardiothorac Vasc Anesth 2002; 16:316-20
176 RANUCCI M, NANO G, PAZZAGLIA A, et al. Platelet mapping and desmopressin reversal of platelet inhibition during emergency carotid endarterectomy. J Cardiothorac Vasc Anesth 2007 ; 21 : 851-4
177 RANUCCI M, PAZZAGLIA A, BIANCHINI C, et al. Body size, gender, and transfusions as determinants of outcome after coronary operations. Ann Thorac Surg 2008 ; 85 : 481-7
178 REITER RA, MAYR F, BLAZICEK H, et al. Desmopressin antagonizes the in vitre platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin. Blood 2003; 102:4594-9
179 RINDER C. Cellular inflammatory response and clinical outcome in cardiac surgery. Curr Opin Anaesthesiol 2006; 19:65-8
180 ROBACK JD, CALDWELL S, CARSON J, et al. Evidence-based practice guidelines for plasma transfusion. Transfusion 2010 ; 50 : 1227-39
181 ROBERTS HR, MONROE DM, ESCOBAR MA. Current concepts of hemostasis. Anesthesiology 2004: 100:722-30
182 ROSEN D, ROSEN K. Elimination of drugs and toxins during cardiopulmonary bypass. J Cardiothorac Vasc Anesth 1997; 11:337-40
183 ROSSAINT R, BOUILLON B, CERNY V, et al. Management of bleeding following major trauma: an updated European guideline. Crit Care 2010; 14:R52
184 ROYSTON D, TAYLOR KM, BIDSTRUP BP, et al. Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet 1987; 2:1289-91
185 ROZENTAL T, SHORE-LESSERSON L. Pharmacologic management of coagulopathy in cardiac surgery: An update. J Cardiothorac Vasc Anesth 2012; 26:660-79
185a RUFF CT, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation : a meta-analysis of randomised trials. Lancet 2014 ; 383:955-62
186 SAGAR UN, KANDULA P. N-acetylcysteine in cardiovascular surgery-associated renal failure: A meta-analysis. Ann Thorac Surg 2009; 87:139-47
187 Sakhuja R, YEH RW, BHATT DL. Antiplatelet agents in acute coronary syndromes. Curr Probl Cardiol 2010; 35:123-70
188 SAMAMA MM, CONTANT G, SPIRO TE, et al. Laboratory assessment of rivaroxaban : a review. Thrombosis Journal 2013; 11:11
188a SCHIELE F, VAN RYN J, Canada K, et al. A specific antidote for dabigatran : functional and structural characterization. Blood 2013; 121:3554-62
189 SCHULMAN S, KEARON C, KAKKAR AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342-52
190 SEARLES B, DARLING E. Ultrafiltration in cardiac surhery. In: MONGERO LB, BECK JR (eds). On bypass. Advanced perfusion techniques. Totowa (NJ, USA): Humana Press 2010, 193-210
191 SEDRAKYAN A, TREASURE T, ELEFTERIADES JA. Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: A systematic review and meta-analysis of randomized clinical trials. J Thorac Cardiovasc Surg 2004; 128:442-8
192 SHAKUR H, ROBERTS I, BAUTISTA R, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2) : a randomised, placebo-controlled trial. Lancet 2010 ; 376 : 23-32
193 SHANN KG, LIKOSKY DS, MURKIN JM, et al. An evidence-based review of the practice of cardiopulmonary bypass in adults: A focus on neurologic injury, glycemic control, hemodilution, and the inflammatory response. J Thorac Cardiovasc Surg 2006; 132:283-90
194 Sharony R, Bizekis CS, Kanchuger M, et al. Off-pump coronary artery bypass grafting reduces mortality and stroke in patients with atheromatous aortas: A case control study. Circulation 2003; 108 (suppl II):15-20
195 SHERWOOD ER, TOLIVER-KINSKY T. Mechanisms of the inflammatory response. Best Pract Res Clin Anaesthesiol 2004; 18:385-405
196 SIÉ P, SAMAMA CM, GODIER A, et al. Chirurgies et actes invasifs chez les patients traités au long cours par un anticoagulant oral anti-IIa ou anti-Xa direct. Propositions du Groupe d’intérêt en hémostase périopératoire (GIHP) et du Groupe d’études sur l’hémostase et la thrombose (GEHT). Ann Fr Anesth Réanim 2011 ; 30 : 645-50
197 SIEGAL D, YUDIN J, KAATZ S, et al. Periprocedural heparin bridging in patients receiving vitamin K antagonists : systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation 2012 ; 126 :1630-9
198 SINAURIDZE EI, PANTELEEV MA, ATAULLAKHANOV FI. Anticoagulant therapy: basic principles, classic approaches and recent developments. Blood Coag Fibrinol 2012; 23:482-93
199 SMIT JW, ROMIJN JA. Acute insulin resistance in myocardial ischemia : causes and consequences. Semin Cardiothorac Vasc Anesth 2006 ; 10 :215-9
200 SNIECINSKI RM, CHANDLER WL. Activation of the hemostatic system during cardiopulmonary bypass. Anesth Analg 2011; 113:1319-33
201 SNIECINSKI RM, HURSTING MJ, PAIDAS MJ, LEVY JH. Etiology and assessment of hypercoagulability with lessons from heparin-induced thrombocytopenia. Anesth Analg 2011; 112: 46-58
202 SNIECINSKI RM, LEVY JH. The inflammatory response to cardiopulmnary bypass. In: MONGERO LB, BECK JR (eds). On bypass. Advanced perfusion techniques. Totowa (NJ, USA): Humana Press 2010, 125-140
203 SPAHN DR, KORTE W. Novel oral anticoagulants. New challenges for anesthesiologists in bleeding patients. Anesthesiology 2012 ; 116 :9-11
204 SPIESS BD. Platelet transfusions : the science behind safety, risks and appropriate applications. Best Pract Res Clin Anaesthesiol 2010 ; 24 : 65-83
205 SPIESS BD, ROYSTON D, LEVY JH, et al. Platelet transfusions during coronary artery bypass graft surgery are associated with serious adverse outcomes. Transfusion 2004 ; 44 : 1143-8
206 STAHL GL, SHERMAN SK, SMITH PK, LEVY JH. Complement activation and cardiac surgery : a novel target for improving outcomes. Anesth Analg 2012 ; 115 :759-71
207 SUN JC, WHITLOCK R, CHENG J, et al. The effect of preoperative aspirin on bleeding, transfusion, myocardial infarction, and mortality in coronary artery bypass surgery : a systematic review of randomized and observational studies. Eur Heart J 2008; 29:1057-71
208 SUNGURTEKIN H, COOK DJ, ORSZULAK TA, et al. Cerebral response to hemodilution during hypothermic cardiopulmonary bypass in adults. Anesth Analg 1999; 89:1078-83
209 SURGENOR SD, KRAMER RS, OLMSTEAD EM, et al. The association of perioperative red blood cell transfusions and decreased long-term survival after cardiac surgery. Anesth Analg 2009; 108:1741-6
210 SWAMINATHAN M, PHILIPS-BUTE BG, CONLON PJ, et al. The association of lowest hematocrit during cardiopulmonary bypass with acute renal injury after coronary artery bypass surgery. Ann Thorac Surg 2003; 76:784-91
211 TAFUR AJ, McBANE R, WYSOKINSKI WE, et al. Predictors of major bleeding in peri-procedural anticoagulation management. J Thromb Haemost 2012; 10:261-7
212 TAFUR AJ, WYSOKINSKI WE, McBANE R, et al. Cancer effect on periprocedural thromboembolism and bleeding in anticoagulated patients. Ann Onc 2012; 23:1998-2005
213 TAKAGI H, KAWAI N, UMEMOTO T. Preoperative statin therapy reduces postoprative all-cause mortality in cardiac surgery : a meta-analysis of controlled studies. J Thorac Cardiovasc Surg 2009 ; 137 :e52-3
214 TANAKA KA, BOLLIGER D, VADIAMUDI R, NIMMO A. Rotational thromboelastometry (ROTEM)-based coagulation management in cardiac surgery and major trauma. J Cardiothorac Vasc Anesth 2012 ; 26 :1083-93
215 TANAKA KA, KOR DJ. Emerging haemostatic agents and patient blood management. Best Pract Res Clin Anaesthesiol 2013 ; 27 : 141-60
216 THAKUR M, AHMED A. A review of thromboelastography. Int J Periop Ultrasound Appl Technol 2012 ; 1 : 25-9
217 THEUSINGER OM, SCHRÖDER CM, EISMON J, et al. The influence of laboratory coagulation tests and clotting factor levels on Rotation Thromboelalstometry (ROTEM™) during major surgery with hemorrhage. Anesth Analg 2013 ; 117 :314-21
218 THIELMANN M, KOTTENBERG E, KLEINBONGARD P, et al. Cardioprotective and prognostic effects of remote ischaemic preconditioning in patients undergoing coronary artery bypass surgery : a single-centre randomised, double-blind, controlled trial. Lancet 2013 ; 382 :597-604
219 TOTH P, MAKRIS M. Prothrombin complex concentrate-related thrombotic risk following anticoagulation reversal. Thromb Haemost 2012; 107:599
220 TRIULZI DJ. Transfusion-related acute lung injury: Current concepts for the clinician. Anesth Analg 2009; 108:70-6
221 TURPIE AG, KREUTZ R, LLAU J, et al. Management consensus guidance for the use of rivaroxaban - an oral, direct factor Xa inhibitor. Thromb Haemost 2012; 108:876-86
222 TURPIE AG, LASSEN MR, DAVIDSON BL, et al, RECORD4 investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty: a randomised trial. Lancet 2009; 373:1673-80
223 UIJTTEWAAL WS, NIJHOF EJ, BRONKHORST PJ, et al. Near-wall excess of platelets induced by lateral migration of erythrocytes in flowing blood. Am J Physiol 1993 ; 264 : H1239-44
224 UMSHEID CA, KOHL BA, WILLIAMS K. Antifibrinolytic use in adult cardiac surgery. Curr Opin Hematol 2007; 14:455-67
225 UNTCH BR, JESKE WP, SCHWARTZ J, et al. Inflammatory and hemostatic activation in patients undergoing off-pump coronary artery bypass grafting. Clin Appl Thromb Hemost 2008; 14-141-8
225a VAN STRATEN AH, HAMAD MA, VAN ZUNDERT AJ, et al. Preoperative hemoglobin level as a predictor of survival after coronary artery bypass grafting : a comparison with the matched general population. Circulation 2009 ; 120 :118-25
225b VAN VEEN JJ, MAKRIS M. Management of perioperative anti-thrombotic therapy. Anaesthesia 2015 ; 70 (Suppl.1) : 58-67
226 VAN WERMESKERKEN GK, LARDENOYE JWH, HILL SE, et al. Intraoperative physiologic variables and outcome in cardiac surgery. Part II. Neurologic outcome. Ann Thorac Surg 2000; 69:1077-83
227 VILES-GONZALEZ JF, ANNAND SX, ZAFAR MU, et al. Tissue factor coagulation pathway: A new therapeutic target in atherothrombosis. J Cardiovasc Pharmacol 2004; 43:669-76
228 VIOLI F, CALVIERI C, FERRO D, PIGNATELLI P. Statins as antithrombotic drugs. Circulation 2013; 127:251-7
229 VUYLSTEKE A, PAGEL C, GERRARD C, et al. The Papworth Bleeding Risk Score : a stratification scheme for identifying cardiac surgery patients at risk of excessive early postoperative bleeding. Eur J Cardiothorac Surg 2011 ; 39 :924-30
230 WALLENTIN L, BECKER RC, BUDAJ A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361:1045-57
231 WALLENTIN L, YUSUF S, EZEKOWITZ MD, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalized ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010; 376:975-83
232 WANG G, BAINBRIDGE D, MARTIN J, et al. The efficacy of an intraoperative cell saver during cardiac surgery: a meta-analysis of randomized trials. Anesth Analg 2009; 109:320-30
233 WARREN OJ, SMITH AJ, ALEXIOU C, et al. The inflammatory response to cardiopulmonary bypass: Part 1 - Mechanisms of pathogenesis. J Cardiothorac Vasc Anesth 2009; 23: 223-31
234 WARREN OJ, WATRET AL, DE WIT KL, et al. The inflammatory response to cardiopulmonary bypass: Part 2 - Anti-inflammatory therapeutic strategies. J Cardiothorac Vasc Anesth 2009; 23: 384-93
235 WEBER CF, DIETRICH W, SPANNAGL M, et al. A point-of-care assessment of the effects of desmopressin on impaired platelet function using Multiple Electrode whole-blood Aggregometry in patients after cardiac surgery. Anesth Analg 2010 ; 110 :702-7
236 WEBER CF, GÖRLINGER K, MEININGER D. Point-of-care testing : a prospective randomized clinical trial of efficacy in coagulopathic cardiac surgery patients. Anesthesiology 2012 ; 117 : 531-47
237 WEBER CF, KLAGES M, ZACHAROWSKI K. Perioperative coagulation management during cardiac surgery. Curr Opin Anaesthesiol 2013 ; 26 : 60-84
238 WEITZ JI, EIKELBOOM JW, SAMAMA MM. New antithrombotic drugs. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (Suppl 2):e120S-e151S
239 WEITZ JI, HIRSH J. New anticoagulant drugs. Chest 2001; 119:95s-107s
240 WEITZ JI, QUINLAN DJ, EIKELBOOM JW. Periprocedural management and approach to bleeding in patients taking dabigatran. Circulation 2012; 126:2428-32
241 WHITLOCK RP, CHAN S, DEVEREAUX PI, et al. Clinical benefit of steroid use in patients undergoing cardiopulmonary bypass : A meta-analysis of randomized trials. Eur Heart J 2008 ; 29 : 2592-600
242 WILLIAMS MR, D’AMBRA AB, BECK JR, et al. A randomized trial of antithrombin concentrate for treatment of heparin resistance. Ann Thorac Surg 2000; 70:873-7
243 Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357:2001-15
244 WOLBERG AS, ALEMAN MM, LEIDERMAN K, MACHLUS KR. Procoagulant activity in hemostasis and thrombosis: Virchow’s triad revisited. Anesth Analg 2012; 114:275-85
245 WYSOKINSKI WE, McBANE RD. Periprocedural bridging management of anticoagulation. Circulation 2012 ; 126 :486-90
246 YANK V, TUOHY CV, LOGAN AC, et al. Systematic review : benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications. Ann Intern Med 2011 ; 154 : 529-40
247 ZAHIR H, BROWN KS, VANDELL AG, et al. Edoxaban effects on bleeding following punch biopsy and reversal by 4-factor prothrombin complex concentrate. Circulation 2015 ; 131:82-90
248 ZAUGG M, SCHAUB MC, FOËX P. Myocardial injury and its prevention in the perioperative setting. Br J Anaesth 2004; 93:21-33